Active ingredient: Fabomotizol (Fabomotizole) Active ingredient concentration (mg): 10
Anxiolytic drug (tranquilizer). Afobazole is a selective non-benzodiazepine anxiolytic. Acting on sigma-1 receptors in the nerve cells of the brain, Afobazole stabilizes GABA / benzodiazepine receptors and restores their sensitivity to endogenous inhibition mediators. Afobazole also increases the bioenergetic potential of neurons and has a neuroprotective effect: restores and protects nerve cells. The effect of the drug is realized mainly in the form of a combination of anxiolytic (anti-anxiety) and light stimulating (activating) effects. Afobazole reduces or eliminates anxiety (preoccupation, misgivings, fears), irritability, tension (fearfulness, tearfulness, anxiety, inability to relax, insomnia, fear), depressed mood, somatic anxiety (muscular, sensory, cardiovascular, respiratory , gastrointestinal symptoms), autonomic disorders (dry mouth, sweating, dizziness), cognitive disorders (difficulty concentrating, impaired memory), incl. arising from stress disorders (adaptation disorders). Especially shown is the use of the drug in individuals with predominantly asthenic personality traits in the form of anxious suspiciousness, uncertainty, increased vulnerability and emotional lability, a tendency to emotional and stressful reactions. The effect of the drug develops for 5-7 days of treatment. The maximum effect is achieved by the end of 4 weeks of treatment and persists after the end of treatment on average 1-2 weeks. Afobazole does not cause muscle weakness, drowsiness and does not have a negative effect on concentration and memory. At its application, addiction, drug addiction and withdrawal syndrome do not develop.
AbsorptionAfter oral administration, Afobazole is well and quickly absorbed from the gastrointestinal tract. Cmax - 0.130 ± 0.073 mcg / ml; Тmax - 0.85 ± 0.13 parts. MetabolismAfobazole undergoes a first-pass effect through the liver, the main metabolic pathways are hydroxylation on the aromatic ring of the benzimidazole cycle and oxidation on the morpholine fragment.Afobazole is intensively distributed in well vascularized organs, it is characterized by rapid transfer from the central pool (blood plasma) to the peripheral (highly vascularized organs and tissues). Excretion of T1 / 2 fabomotisol when the drug is taken orally is 0.82 ± 0.54 h. Short T1 / 2 is due to intense biotransformation of the drug and the rapid distribution of blood plasma in organs and tissues. The drug is excreted mainly in the form of metabolites and partially unchanged with urine and feces. With long-term use does not accumulate in the body.
Generalized anxiety disorders; neurasthenia; adjustment disorders, bronchial asthma; irritable bowel syndrome; systemic lupus erythematosus; coronary heart disease; hypertonic disease; dermatological, oncological and other diseases; sleep disorders associated with anxiety; neurocirculatory dystonia; premenstrual syndrome; alcohol withdrawal syndrome; for relief, withdrawal when quitting smoking.
Individual intolerance to the drug; galactose intolerance, lactase deficiency or glucose-galactose malabsorption; pregnancy, lactation; child, age up to 18 years.
Do not exceed recommended doses.
Use during pregnancy and lactation
The use of the drug Afobazole is contraindicated during pregnancy. If you need to use the drug during lactation, breastfeeding should be stopped.
Dosage and administration
It is applied inside, after food. Optimum single doses - 10 mg; daily allowance - 30 mg, divided into 3 doses during the day, the duration of the course use of the drug is 2-4 weeks. If necessary, on the recommendation of a doctor, the daily dose of the drug can be increased to 60 mg, and the duration of treatment up to 3 months.
Allergic reactions, headache.
Symptoms: with a significant overdose and intoxication, it is possible to develop a sedative effect and increased drowsiness without manifestations of muscle relaxation. Treatment: As an emergency, caffeine 20% solution is used in ampoules of 1.0 ml 2-3 times / day p / k.
Interaction with other drugs
Afobazole does not interact with ethanol and has no effect on the hypnotic effect of thiopental. Amplifies the anticonvulsant effect of carbamazepine. It causes an increase in the anxiolytic effect of diazepam.
Impact on the ability to drive vehicles and control mechanisms The drug does not adversely affect the driving of vehicles and the performance of potentially hazardous activities that require high concentration of attention and speed of psychomotor reactions.